14 August 2017 Research: Optimization and interpretation of serial QuantiFERON testing to measure acquisition of M. tuberculosis infection
Latest Research Optimization and interpretation of serial QuantiFERON testing to measure acquisition of M. tuberculosis infection
SATVI authors have published research in which they find that the implementation of optimized procedures and a more rigorous QuantiFERON-TB conversion definition, an increase from IFNy<0.2 to >0.7 IU/mL, would allow more definitive detection of recent M.tb infection and potentially improve identification of those more likely to develop disease.
The article titled “Optimization and interpretation of serial QuantiFERON testing to measure acquisition of M. tuberculosis infection” appeared in the American Journal of Respiratory and Critical Care Medicine.
Generally in practice, the interpretation of serial QuantiFERON-TB Gold in-tube tests, the gold standard for diagnosing latent M. tuberculosis infection, is complicated by immunological and technical variability. In the study the analysis of large, independent cohorts provided immunological and epidemiological evidence that QuantiFERON-TB IFNy values between 0.2 and 0.7 IU/mL are confounded by immunological and technical variability. The study reports on optimized procedures to reduce variability, which are stricter than the manufacturer’s recommendations, as well as a more rigorous definition of QuantiFERON-TB conversion.
These findings are important for the revision of guidelines for the interpretation of serial QuantiFERON-TB testing for clinical decision-making and for clinical trials in which acquisition of M. tuberculosis infection, defined by conversion of the QuantiFERON-TB assay, is a measure of vaccine efficacy.